{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:17:47Z","timestamp":1791562667385,"version":"4.3.4"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","award":["2016 FGR 0045"],"award-info":[{"award-number":["2016 FGR 0045"]}],"id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association Inc","doi-asserted-by":"publisher","award":["16GRNT31000010"],"award-info":[{"award-number":["16GRNT31000010"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL107887"],"award-info":[{"award-number":["HL107887"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50AT002776"],"award-info":[{"award-number":["P50AT002776"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["316213987"],"award-info":[{"award-number":["316213987"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB 1278 PolyTarget"],"award-info":[{"award-number":["SFB 1278 PolyTarget"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.bcp.2021.114759","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T10:44:44Z","timestamp":1630665884000},"page":"114759","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"special_numbering":"C","title":["Untangling the web of 5-lipoxygenase-derived products from a molecular and structural perspective: The battle between pro- and anti-inflammatory lipid mediators"],"prefix":"10.1016","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6706-811X","authenticated-orcid":false,"given":"Nathaniel C.","family":"Gilbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia E.","family":"Newcomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Werz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bcp.2021.114759_b0005","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1073\/pnas.76.5.2148","article-title":"Arachidonic acid metabolism in polymorphonuclear leukocytes: effects of ionophore A23187","volume":"76","author":"Borgeat","year":"1979","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"9","key":"10.1016\/j.bcp.2021.114759_b0010","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1073\/pnas.76.9.4275","article-title":"Leukotriene C: a slow-reacting substance from murine mastocytoma cells","volume":"76","author":"Murphy","year":"1979","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"5790","key":"10.1016\/j.bcp.2021.114759_b0015","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/288484a0","article-title":"Leukotrienes are potent constrictors of human bronchi","volume":"288","author":"Dahl\u00e9n","year":"1980","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.bcp.2021.114759_b0020","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1073\/pnas.83.12.4175","article-title":"Characterization of leukotriene A4 synthase from murine mast cells: evidence for its identity to arachidonate 5-lipoxygenase","volume":"83","author":"Shimizu","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.bcp.2021.114759_b0025","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1177\/106002809603000725","article-title":"Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma","volume":"30","author":"Wenzel","year":"1996","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.bcp.2021.114759_b0030","doi-asserted-by":"crossref","unstructured":"Funk, C. D. Leukotriene inflammatory mediators meet their match. Sci Transl Med 3, 66ps63, 10.1126\/scitranslmed.3002040 (2011).","DOI":"10.1126\/scitranslmed.3002040"},{"issue":"6014","key":"10.1016\/j.bcp.2021.114759_b0035","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1126\/science.1197203","article-title":"The structure of human 5-lipoxygenase","volume":"331","author":"Gilbert","year":"2011","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.bcp.2021.114759_b0040","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/s41589-020-0544-7","article-title":"Structural and mechanistic insights into 5-lipoxygenase inhibition by natural products","volume":"16","author":"Gilbert","year":"2020","journal-title":"Nat. Chem. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114759_b0045","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-13490-1","article-title":"Feasibility and physiological relevance of designing highly potent aminopeptidase-sparing leukotriene A4 hydrolase inhibitors","volume":"7","author":"Numao","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2021.114759_b0050","doi-asserted-by":"crossref","first-page":"7769","DOI":"10.1021\/acs.jmedchem.9b00555","article-title":"Discovery of the Oral Leukotriene C4 Synthase Inhibitor (1S,2S)-2-({5-[(5-Chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic Acid (AZD9898) as a New Treatment for Asthma","volume":"62","author":"Rosensch\u00f6ld","year":"2019","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2021.114759_b0055","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1124\/jpet.115.227157","article-title":"Tandem Benzophenone Amino Pyridines, Potent and Selective Inhibitors of Human Leukotriene C4 Synthase","volume":"355","author":"Kleinschmidt","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"8","key":"10.1016\/j.bcp.2021.114759_b0060","doi-asserted-by":"crossref","first-page":"4994","DOI":"10.1074\/jbc.M114.599035","article-title":"Inhibition of 5-lipoxygenase selectively triggers disruption of c-Myc signaling in prostate cancer cells","volume":"290","author":"Sarveswaran","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2021.114759_b0065","doi-asserted-by":"crossref","first-page":"R85","DOI":"10.1186\/ar2461","article-title":"A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee","volume":"10","author":"Sengupta","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.bcp.2021.114759_b0070","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/s41398-017-0017-2","article-title":"The direct role of 5-lipoxygenase on tau pathology, synaptic integrity and cognition in a mouse model of tauopathy","volume":"7","author":"Vagnozzi","year":"2017","journal-title":"Transl. Psychiatry"},{"issue":"2","key":"10.1016\/j.bcp.2021.114759_b0075","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/cvr\/cvq016","article-title":"The 5-lipoxygenase\/leukotriene pathway in preclinical models of cardiovascular disease","volume":"86","author":"Poeckel","year":"2010","journal-title":"Cardiovasc. Res."},{"issue":"5","key":"10.1016\/j.bcp.2021.114759_b0080","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1096\/fj.201500210R","article-title":"5-Lipoxygenase-activating protein rescues activity of 5-lipoxygenase mutations that delay nuclear membrane association and disrupt product formation","volume":"30","author":"Gerstmeier","year":"2016","journal-title":"FASEB J."},{"issue":"41","key":"10.1016\/j.bcp.2021.114759_b0085","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1021\/acs.biochem.5b00930","article-title":"Identification of the Substrate Access Portal of 5-Lipoxygenase","volume":"54","author":"Mitra","year":"2015","journal-title":"Biochemistry"},{"issue":"7503","key":"10.1016\/j.bcp.2021.114759_b0090","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature13479","article-title":"Pro-resolving lipid mediators are leads for resolution physiology","volume":"510","author":"Serhan","year":"2014","journal-title":"Nature"},{"issue":"6255","key":"10.1016\/j.bcp.2021.114759_b0095","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/343282a0","article-title":"Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis","volume":"343","author":"Dixon","year":"1990","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.bcp.2021.114759_b0100","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1161\/01.ATV.0000222960.43792.ff","article-title":"Lipoxygenase pathways as mediators of early inflammatory events in atherosclerosis","volume":"26","author":"Funk","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bcp.2021.114759_b0105","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0090-6980(02)00036-9","article-title":"Lipoxygenase genes and their targeted disruption","volume":"68-69","author":"Funk","year":"2002","journal-title":"Prostaglandins Other Lipid Mediat."},{"issue":"49","key":"10.1016\/j.bcp.2021.114759_b0110","doi-asserted-by":"crossref","first-page":"38787","DOI":"10.1074\/jbc.M006136200","article-title":"The N-terminal domain of 5-lipoxygenase binds calcium and mediates calcium stimulation of enzyme activity","volume":"275","author":"Hammarberg","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"15","key":"10.1016\/j.bcp.2021.114759_b0115","doi-asserted-by":"crossref","first-page":"13167","DOI":"10.1074\/jbc.M112393200","article-title":"Molecular basis of the specific subcellular localization of the C2-like domain of 5-lipoxygenase","volume":"277","author":"Kulkarni","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2021.114759_b0120","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/pro.2626","article-title":"The structural basis for specificity in lipoxygenase catalysis","volume":"24","author":"Newcomer","year":"2015","journal-title":"Protein science : a publication of the Protein Society"},{"issue":"12","key":"10.1016\/j.bcp.2021.114759_b0125","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.1096\/fj.13-235952","article-title":"Structure and interaction with phospholipids of a prokaryotic lipoxygenase from Pseudomonas aeruginosa","volume":"27","author":"Garreta","year":"2013","journal-title":"FASEB J."},{"issue":"9","key":"10.1016\/j.bcp.2021.114759_b0130","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.str.2012.06.003","article-title":"Crystal structure of 12-lipoxygenase catalytic-domain-inhibitor complex identifies a substrate-binding channel for catalysis","volume":"20","author":"Xu","year":"2012","journal-title":"Structure"},{"issue":"12","key":"10.1016\/j.bcp.2021.114759_b0135","doi-asserted-by":"crossref","first-page":"8562","DOI":"10.1074\/jbc.M113.543777","article-title":"The structure of human 15-lipoxygenase-2 with a substrate mimic","volume":"289","author":"Kobe","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"46","key":"10.1016\/j.bcp.2021.114759_b0140","doi-asserted-by":"crossref","first-page":"31905","DOI":"10.1074\/jbc.M114.599662","article-title":"Crystal structure of a lipoxygenase in complex with substrate: the arachidonic acid-binding site of 8R-lipoxygenase","volume":"289","author":"Neau","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2021.114759_b0145","doi-asserted-by":"crossref","first-page":"15579","DOI":"10.1073\/pnas.0406727101","article-title":"A single active site residue directs oxygenation stereospecificity in lipoxygenases: stereocontrol is linked to the position of oxygenation","volume":"101","author":"Coffa","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.bcp.2021.114759_b0150","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.chembiol.2007.04.007","article-title":"Control of oxygenation in lipoxygenase and cyclooxygenase catalysis","volume":"14","author":"Schneider","year":"2007","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bcp.2021.114759_b0155","first-page":"179","article-title":"Development of novel leukotriene\u2013based anti-asthma drugs: MK-886 and MK-571","volume":"34","author":"Young","year":"1991","journal-title":"Agents Actions Suppl."},{"issue":"5","key":"10.1016\/j.bcp.2021.114759_b0160","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1139\/y89-073","article-title":"L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2 - dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor","volume":"67","author":"Gillard","year":"1989","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2021.114759_b0165","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1110\/ps.8.3.689","article-title":"Common structural features of MAPEG \u2013 a widespread superfamily of membrane associated proteins with highly divergent functions in eicosanoid and glutathione metabolism","volume":"8","author":"Jakobsson","year":"1999","journal-title":"Protein Sci. Publ. Protein Soc."},{"issue":"5837","key":"10.1016\/j.bcp.2021.114759_b0170","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1126\/science.1144346","article-title":"Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein","volume":"317","author":"Ferguson","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.bcp.2021.114759_b0175","first-page":"31","article-title":"Amino acid residues of 5-lipoxygenase-activating protein critical for the binding of leukotriene biosynthesis inhibitors","volume":"6","author":"Vickers","year":"1993","journal-title":"J Lipid Mediat"},{"key":"10.1016\/j.bcp.2021.114759_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2020.129800","article-title":"Structure-based, multi-targeted drug discovery approach to eicosanoid inhibition: Dual inhibitors of mPGES-1 and 5-lipoxygenase activating protein (FLAP)","volume":"1865","author":"Ho","year":"2021","journal-title":"Biochim. Biophys. Acta, Gen. Subj."},{"issue":"7153","key":"10.1016\/j.bcp.2021.114759_b0185","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nature06009","article-title":"Structural basis for synthesis of inflammatory mediators by human leukotriene C4 synthase","volume":"448","author":"Molina","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2021.114759_b0190","doi-asserted-by":"crossref","first-page":"D390","DOI":"10.1093\/nar\/gky1047","article-title":"The MemProtMD database: a resource for membrane-embedded protein structures and their lipid interactions","volume":"47","author":"Newport","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"7","key":"10.1016\/j.bcp.2021.114759_b0195","doi-asserted-by":"crossref","first-page":"e0228607","DOI":"10.1371\/journal.pone.0228607","article-title":"Arachidonic acid promotes the binding of 5-lipoxygenase on nanodiscs containing 5-lipoxygenase activating protein in the absence of calcium-ions","volume":"15","author":"Kumar","year":"2020","journal-title":"PLoS ONE"},{"issue":"22","key":"10.1016\/j.bcp.2021.114759_b0200","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1091\/mbc.e12-06-0489","article-title":"The nuclear membrane leukotriene synthetic complex is a signal integrator and transducer","volume":"23","author":"Bair","year":"2012","journal-title":"Mol. Biol. Cell"},{"issue":"51","key":"10.1016\/j.bcp.2021.114759_b0205","doi-asserted-by":"crossref","first-page":"20434","DOI":"10.1073\/pnas.0808211106","article-title":"The nuclear membrane organization of leukotriene synthesis","volume":"105","author":"Mandal","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"17","key":"10.1016\/j.bcp.2021.114759_b0210","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1073\/pnas.0308523101","article-title":"The membrane organization of leukotriene synthesis","volume":"101","author":"Mandal","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.bcp.2021.114759_b0215","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1472-6807-7-44","article-title":"The role of hydrophobic interactions in positioning of peripheral proteins in membranes","volume":"7","author":"Lomize","year":"2007","journal-title":"BMC Struct. Biol."},{"key":"10.1016\/j.bcp.2021.114759_b0220","doi-asserted-by":"crossref","first-page":"D370","DOI":"10.1093\/nar\/gkr703","article-title":"OPM database and PPM web server: resources for positioning of proteins in membranes","volume":"40","author":"Lomize","year":"2012","journal-title":"Nucleic Acids Res."},{"issue":"19","key":"10.1016\/j.bcp.2021.114759_b0225","doi-asserted-by":"crossref","first-page":"16520","DOI":"10.1074\/jbc.M011205200","article-title":"5-Lipoxygenase interacts with coactosin-like protein","volume":"276","author":"Provost","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"35","key":"10.1016\/j.bcp.2021.114759_b0230","doi-asserted-by":"crossref","first-page":"13150","DOI":"10.1073\/pnas.0605150103","article-title":"Coactosin-like protein supports 5-lipoxygenase enzyme activity and up-regulates leukotriene A4 production","volume":"103","author":"Rakonjac","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.bcp.2021.114759_b0235","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1042\/BJ20090856","article-title":"Coactosin-like protein functions as a stabilizing chaperone for 5-lipoxygenase: role of tryptophan 102","volume":"425","author":"Esser","year":"2009","journal-title":"Biochem. J."},{"issue":"7","key":"10.1016\/j.bcp.2021.114759_b0240","doi-asserted-by":"crossref","first-page":"e0132607","DOI":"10.1371\/journal.pone.0132607","article-title":"The Intracellular Localisation and Phosphorylation Profile of the Human 5-Lipoxygenase \u039413 Isoform Differs from That of Its Full Length Counterpart","volume":"10","author":"Allain","year":"2015","journal-title":"PLoS ONE"},{"issue":"31","key":"10.1016\/j.bcp.2021.114759_b0245","doi-asserted-by":"crossref","first-page":"11371","DOI":"10.1073\/pnas.1410983111","article-title":"Roles of coactosin-like protein (CLP) and 5-lipoxygenase-activating protein (FLAP) in cellular leukotriene biosynthesis","volume":"111","author":"Basavarajappa","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"23","key":"10.1016\/j.bcp.2021.114759_b0250","doi-asserted-by":"crossref","first-page":"13438","DOI":"10.1016\/S0021-9258(18)77365-1","article-title":"The mechanism of leukotriene B4 export from human polymorphonuclear leukocytes","volume":"265","author":"Lam","year":"1990","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2021.114759_b0255","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0022-2275(20)32448-2","article-title":"Characterization of a leukotriene C4 export mechanism in human platelets: possible involvement of multidrug resistance-associated protein 1","volume":"40","author":"Sjolinder","year":"1999","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bcp.2021.114759_b0260","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1432-1033.1988.tb13971.x","article-title":"Human endothelial cells stimulate leukotriene synthesis and convert granulocyte released leukotriene A4 into leukotrienes B4, C4, D4 and E4","volume":"173","author":"Claesson","year":"1988","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.bcp.2021.114759_b0265","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/pro.3509","article-title":"Emerging structural biology of lipid G protein-coupled receptors","volume":"28","author":"Audet","year":"2019","journal-title":"Protein Sci."},{"key":"10.1016\/j.bcp.2021.114759_b0270","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd.2016.230","article-title":"A comprehensive map of molecular drug targets","volume":"16","author":"Santos","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2021.114759_b0275","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.tibs.2014.03.002","article-title":"Allosteric sodium in class A GPCR signaling","volume":"39","author":"Katritch","year":"2014","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.bcp.2021.114759_b0280","doi-asserted-by":"crossref","first-page":"12454","DOI":"10.1074\/jbc.M011361200","article-title":"Hydroxyeicosanoids bind to and activate the low affinity leukotriene B4 receptor, BLT2","volume":"276","author":"Yokomizo","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2021.114759_b0285","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1084\/jem.20072329","article-title":"12(S)-Hydroxyheptadeca-5Z, 8E, 10E-trienoic acid is a natural ligand for leukotriene B4 receptor 2","volume":"205","author":"Okuno","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcp.2021.114759_b0290","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/42506","article-title":"A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis","volume":"387","author":"Yokomizo","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2021.114759_b0295","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1021\/acs.orglett.9b01554","article-title":"An Alternative Pathway to Leukotriene B(4) Enantiomers Involving a 1,8-Diol-Forming Reaction of an Algal Oxylipin","volume":"21","author":"Jagusch","year":"2019","journal-title":"Org. Lett."},{"key":"10.1016\/j.bcp.2021.114759_b0300","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1074\/jbc.M409821200","article-title":"Phosphorylation-independent beta-arrestin translocation and internalization of leukotriene B4 receptors","volume":"280","author":"Jala","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2021.114759_b0305","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.smim.2017.08.007","article-title":"Recent advances in clinical development of leukotriene B4 pathway drugs","volume":"33","author":"Bhatt","year":"2017","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.bcp.2021.114759_b0310","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nchembio.2547","article-title":"Na(+)-mimicking ligands stabilize the inactive state of leukotriene B(4) receptor BLT1","volume":"14","author":"Hori","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bcp.2021.114759_b0315","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1038\/s41467-021-23149-1","article-title":"Structural insights on ligand recognition at the human leukotriene B4 receptor 1","volume":"12","author":"Michaelian","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2021.114759_b0320","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41586-019-1141-3","article-title":"Structural basis of ligand recognition at the human MT(1) melatonin receptor","volume":"569","author":"Stauch","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2021.114759_b0325","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/j.2042-7158.1974.tb09208.x","article-title":"Inhibition of eosinophil chemotaxis by the antagonist of slow reacting substance of anaphylaxis\u2013compound FPL 55712","volume":"26","author":"Jones","year":"1974","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114759_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2021.02.057","article-title":"A Boxed Warning for Montelukast: The FDA Perspective","author":"Clarridge","year":"2021","journal-title":"J Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.bcp.2021.114759_b0335","doi-asserted-by":"crossref","first-page":"eaax2518","DOI":"10.1126\/sciadv.aax2518","article-title":"Structure-based mechanism of cysteinyl leukotriene receptor inhibition by antiasthmatic drugs","volume":"5","author":"Luginina","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bcp.2021.114759_b0340","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1038\/s41467-019-13348-2","article-title":"Structural basis of ligand selectivity and disease mutations in cysteinyl leukotriene receptors","volume":"10","author":"Gusach","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2021.114759_b0345","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/0006-291X(84)91486-4","article-title":"Trihydroxytetraenes: a novel series of compounds formed from arachidonic acid in human leukocytes","volume":"118","author":"Serhan","year":"1984","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2021.114759_b0350","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1073\/pnas.81.17.5335","article-title":"Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes","volume":"81","author":"Serhan","year":"1984","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.bcp.2021.114759_b0355","first-page":"2015","article-title":"Transcellular biosynthesis of eicosanoid lipid mediators","volume":"377\u2013382","author":"Capra","year":"1851","journal-title":"Biochim. Biophys. Acta, Gene Struct. Expression"},{"key":"10.1016\/j.bcp.2021.114759_b0360","doi-asserted-by":"crossref","first-page":"16340","DOI":"10.1016\/S0021-9258(18)66571-8","article-title":"Lipoxin A Stereochemistry and biosynthesis","volume":"261","author":"Serhan","year":"1986","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2021.114759_b0365","doi-asserted-by":"crossref","first-page":"9475","DOI":"10.1073\/pnas.92.21.9475","article-title":"Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions","volume":"92","author":"Claria","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.bcp.2021.114759_b0370","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.plefa.2005.05.002","article-title":"Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution","volume":"73","author":"Serhan","year":"2005","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"10.1016\/j.bcp.2021.114759_b0375","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1042\/EBC20200018","article-title":"Specialized pro-resolving mediator network: an update on production and actions","volume":"64","author":"Chiang","year":"2020","journal-title":"Essays Biochem."},{"key":"10.1016\/j.bcp.2021.114759_b0380","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1172\/JCI97943","article-title":"Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators","volume":"128","author":"Serhan","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2021.114759_b0385","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1096\/fj.201802509R","article-title":"Targeting biosynthetic networks of the proinflammatory and proresolving lipid metabolome","volume":"33","author":"Werner","year":"2019","journal-title":"FASEB J."},{"key":"10.1016\/j.bcp.2021.114759_b0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105556","article-title":"Anti-inflammatory celastrol promotes a switch from leukotriene biosynthesis to formation of specialized pro-resolving lipid mediators","volume":"167","author":"Pace","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2021.114759_b0395","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3389\/fphar.2019.00797","article-title":"Ginkgolic Acid is a Multi-Target Inhibitor of Key Enzymes in Pro-Inflammatory Lipid Mediator Biosynthesis","volume":"10","author":"Gerstmeier","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114759_b0400","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.bcp.2019.03.003","article-title":"Novel benzoxanthene lignans that favorably modulate lipid mediator biosynthesis: A promising pharmacological strategy for anti-inflammatory therapy","volume":"165","author":"Gerstmeier","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114759_b0405","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ejmech.2018.07.031","article-title":"Discovery of a benzenesulfonamide-based dual inhibitor of microsomal prostaglandin E(2) synthase-1 and 5-lipoxygenase that favorably modulates lipid mediator biosynthesis in inflammation","volume":"156","author":"Cheung","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2021.114759_b0410","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41467-017-02538-5","article-title":"Human macrophages differentially produce specific resolvin or leukotriene signals that depend on bacterial pathogenicity","volume":"9","author":"Werz","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2021.114759_b0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108247","article-title":"Staphylococcus aureus-Derived \u03b1-Hemolysin Evokes Generation of Specialized Pro-resolving Mediators Promoting Inflammation Resolution","volume":"33","author":"Jordan","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.bcp.2021.114759_b0420","doi-asserted-by":"crossref","first-page":"C39","DOI":"10.1152\/ajpcell.00024.2014","article-title":"Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue","volume":"307","author":"Colas","year":"2014","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.bcp.2021.114759_b0425","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jasms.2006.09.002","article-title":"Resolvin D1, protectin D1, and related docosahexaenoic acid-derived products: Analysis via electrospray\/low energy tandem mass spectrometry based on spectra and fragmentation mechanisms","volume":"18","author":"Hong","year":"2007","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"10.1016\/j.bcp.2021.114759_b0430","doi-asserted-by":"crossref","first-page":"14530","DOI":"10.1073\/pnas.1410851111","article-title":"Resolvin D1 limits 5-lipoxygenase nuclear localization and leukotriene B4 synthesis by inhibiting a calcium-activated kinase pathway","volume":"111","author":"Fredman","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.bcp.2021.114759_b0435","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1189\/jlb.1204747","article-title":"Inhibition of 5-lipoxygenase-activating protein abrogates experimental liver injury: role of Kupffer cells","volume":"78","author":"Titos","year":"2005","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.bcp.2021.114759_b0440","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.1096\/fj.15-275487","article-title":"Lipoxin and resolvin biosynthesis is dependent on 5-lipoxygenase activating protein","volume":"29","author":"Lehmann","year":"2015","journal-title":"FASEB J."},{"key":"10.1016\/j.bcp.2021.114759_b0445","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1182\/blood.V99.3.1044","article-title":"Activation of 5-lipoxygenase by cell stress is calcium independent in human polymorphonuclear leukocytes","volume":"99","author":"Werz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2021.114759_b0450","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1254\/jphs.09012FP","article-title":"Oxymetazoline inhibits and resolves inflammatory reactions in human neutrophils","volume":"110","author":"Beck-Speier","year":"2009","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2021.114759_b0455","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25153374","article-title":"Fatty Acid Allosteric Regulation of C-H Activation in Plant and Animal Lipoxygenases","volume":"25","author":"Offenbacher","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2021.114759_b0460","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1084\/jem.20052371","article-title":"Neutrophil-derived leukotriene B4 is required for inflammatory arthritis","volume":"203","author":"Chen","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcp.2021.114759_b0465","doi-asserted-by":"crossref","first-page":"R83","DOI":"10.1186\/ar2717","article-title":"Expression of 5-lipoxygenase and 15-lipoxygenase in rheumatoid arthritis synovium and effects of intraarticular glucocorticoids","volume":"11","author":"Gheorghe","year":"2009","journal-title":"Arthritis. Res. Ther."},{"key":"10.1016\/j.bcp.2021.114759_b0470","article-title":"Montelukast Use Decreases Cardiovascular Events in Asthmatics","volume":"11","author":"Hoxha","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114759_b0475","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.bbrc.2012.01.068","article-title":"Lipid metabolism enzyme 5-LOX and its metabolite LTB4 are capable of activating transcription factor NF-\u03baB in hepatoma cells","volume":"418","author":"Zhao","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2021.114759_b0480","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1158\/0008-5472.CAN-04-4090","article-title":"5-Lipoxygenase, a marker for early pancreatic intraepithelial neoplastic lesions","volume":"65","author":"Hennig","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2021.114759_b0485","doi-asserted-by":"crossref","first-page":"10512","DOI":"10.1523\/JNEUROSCI.5183-12.2013","article-title":"Modulation of 5-lipoxygenase in proteotoxicity and Alzheimer's disease","volume":"33","author":"Valera","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bcp.2021.114759_b0490","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.biopsych.2013.04.009","article-title":"5-lipoxygenase activating protein reduction ameliorates cognitive deficit, synaptic dysfunction, and neuropathology in a mouse model of Alzheimer's disease","volume":"74","author":"Giannopoulos","year":"2013","journal-title":"Biol. Psychiatry"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221003750?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221003750?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T21:36:27Z","timestamp":1778708187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295221003750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":98,"alternative-id":["S0006295221003750"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114759","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Untangling the web of 5-lipoxygenase-derived products from a molecular and structural perspective: The battle between pro- and anti-inflammatory lipid mediators","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114759","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114759"}}